Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-PEDS-OLE long-term inclisiran extension in pediatric familial hypercholesterolemia
2023-507278-41-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 26
01
Overview
Phase 3, open-label, single-arm trial of inclisiran in familial hypercholesterolemia (FH), sponsored by Novartis. Primary endpoint: Treatment-emergent adverse events and long-term safety. Planned start Feb 2023; status: authorised.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2023-507278-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507278-41-00.